title: Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group.
abstract: We present here the long-term results of three randomized clinical trials conducted on children with newly diagnosed acute lymphoblastic leukemia (ALL) between 1983 and 1998 by the Children Leukemia Cooperative Group (CLCG) from EORTC. In study 58831/32, the overall event-free survival (EFS) rates (+/- s.e.) at 6 and 10 years were 66% +/- 1.8% and 65% +/- 1.8%, respectively, and the risk of isolated central nervous system (CNS) relapse was 6% +/- 1% and 7% +/- 1%, respectively. In patients with a standard risk of relapse the omission of cyclophosphamide had no adverse effect on disease-free survival rates at 10 years (trial 58831). In medium- and high-risk patients the omission of radiotherapy did not increase the risk of CNS or systemic relapse (trial 58832). In study 58881 (1989-1998) the overall EFS rate at 8 years was 68.4% +/- 1.2% and the risk of isolated CNS relapse was 4.2%+/-0.5%. In this trial which adressed three randomized questions, the following results were obtained: the combination of cytarabine at high doses with methotrexate at high doses during interval therapy did not improve prognosis. The addition of 6-mercaptopurine iv during maintenance increased the risk of late relapse. E. coli asparaginase was more toxic and has a higher efficacy than Erwinia asparaginase. Leukocyte counts >100 x 10(9)/l, specific genetic abnormalities, a poor initial response to steroids or a high level of minimal residual disease at early time points were consistently associated with an adverse prognosis in the 58881 trial.
authors.affiliation: Department of Hemato-Immunology, Robert Debré Hospital, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Vilmer
authors.forename: S
authors.initials: S
authors.lastname: Suciu
authors.forename: A
authors.initials: A
authors.lastname: Ferster
authors.forename: Y
authors.initials: Y
authors.lastname: Bertrand
authors.forename: H
authors.initials: H
authors.lastname: Cavé
authors.forename: A
authors.initials: A
authors.lastname: Thyss
authors.forename: Y
authors.initials: Y
authors.lastname: Benoit
authors.forename: N
authors.initials: N
authors.lastname: Dastugue
authors.forename: M
authors.initials: M
authors.lastname: Fournier
authors.forename: G
authors.initials: G
authors.lastname: Souillet
authors.forename: A M
authors.initials: AM
authors.lastname: Manel
authors.forename: A
authors.initials: A
authors.lastname: Robert
authors.forename: B
authors.initials: B
authors.lastname: Nelken
authors.forename: F
authors.initials: F
authors.lastname: Millot
authors.forename: P
authors.initials: P
authors.lastname: Lutz
authors.forename: X
authors.initials: X
authors.lastname: Rialland
authors.forename: F
authors.initials: F
authors.lastname: Mechinaud
authors.forename: P
authors.initials: P
authors.lastname: Boutard
authors.forename: C
authors.initials: C
authors.lastname: Behar
authors.forename: J M
authors.initials: JM
authors.lastname: Chantraine
authors.forename: E
authors.initials: E
authors.lastname: Plouvier
authors.forename: G
authors.initials: G
authors.lastname: Laureys
authors.forename: P
authors.initials: P
authors.lastname: Brock
authors.forename: A
authors.initials: A
authors.lastname: Uyttebroeck
authors.forename: G
authors.initials: G
authors.lastname: Margueritte
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
authors.forename: L
authors.initials: L
authors.lastname: Norton
authors.forename: N
authors.initials: N
authors.lastname: Francotte
authors.forename: J
authors.initials: J
authors.lastname: Gyselinck
authors.forename: C
authors.initials: C
authors.lastname: Waterkeyn
authors.forename: G
authors.initials: G
authors.lastname: Solbu
authors.forename: N
authors.initials: N
authors.lastname: Philippe
authors.forename: J
authors.initials: J
authors.lastname: Otten
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012074:Remission Induction